

CUMULATIVE INDEX
VOLUME 21, NUMBERS 1-4, 1978



Abortion

- in adolescent pregnancies, 1165-1166, 1175-1190
 - anesthesia and analgesia in, 1181-1183
 - and cervical size, 1181
 - counseling with, 1179-1180
 - demography of, 1175-1176
 - first-trimester, 1185-1187
 - laminaria tents in, 1185-1187
 - legal problems in, 1181
 - mortality rate in, 1176-1178
 - postabortion instructions, 1188-1189
 - preabortion procedures, 1183-1185
 - and preservation of childbearing function, 1178-1179
 - and Rh determination, 1181
 - second-trimester, 1187-1189
- infections from, 461-462
- spontaneous
 - and α -fetoprotein levels, 344
 - and α -2-glycoprotein levels, 347
 - placental lactogen levels in, 365-366
- therapeutic, in cardiac disease, 433
- Abruptio placentae
 - and fibrinogen degradation products in serum, 348
 - ultrasonic diagnosis of, 323
- Abscess, Bartholin's duct
 - marsupialization in, 966, 975-977
 - Word catheter in, 973, 977
- Acetazolamide, in hypertension with pregnancy, 640
- Acid-base homeostasis
 - kidney responses in, 851-852
 - maternal-fetal, 585-589
- Acidosis, fetal
 - primary, during hypoxia, 579-580
 - secondary, 581
- Acne, and androgen metabolism in skin, 121
- Acromegaly, hyperprolactinemia in, 132

ACTH

- fetal production of, and premature labor, 534
- stimulation tests in childhood, 1143
- Addison's disease, hyperprolactinemia in, 132
- Adenosine triphosphate, and myometrial contractions, 141
- Adolescence
 - abortion in, 1165-1166, 1175-1190. *See also* Abortion
 - adrenarche in, 109, 1143-1144
 - endocrine changes in, 69-75, 1143-1144
 - hypothalamic-pituitary function in, 1145-1146
 - and initiation of puberty, 1146-1147
 - menarche in, 72-73, 109, 1142-1143
 - ovarian function in, 1144
 - and physical changes of puberty, 1137-1140
 - pregnancy in, 1135-1231
 - and adoption of infants, 1166
 - antecedents of, 1151-1159
 - complications of, 1191-1197
 - and contraceptive knowledge and use, 1155-1156, 1163, 1200, 1208-1212
 - and education for family life, 1154, 1200-1202
 - and failures of educational programs, 1154-1155
 - and family relationships, 1163-1164
 - four-year follow-up of, 1221-1222
 - and infant outcome, 1196
 - intervention programs for, 1168-1171
 - and Johns Hopkins program, 1231-1232
 - and lack of birth-control services, 1155-1156
 - long-range outcome of, 1215-1232
 - and need for early pregnancy detection, 1156
 - nutritional needs in, 1202-1208
 - and prognosis for mothers, 1166-1167

- Adolescence, pregnancy in (*continued*)
 psychological issues in, 1156-1158, 1162
 reactions to, 1164-1165
 seven-year follow-up of, 1222-1227
 and sexual environment, 1153-1154
 social factors in, 1152-1153
 and Temple University program,
 1170-1171
 twelve-year follow-up of, 1227-1230
 and YMED program in New York,
 1168-1170
 and secondary sexual development,
 1140-1142
 sexual behavior in, 1161-1162, 1199-1200
 and counseling programs, 235-248
- Adoption, maternal reactions to, in
 adolescence, 1166
- Adrenarche, 109, 1143-1144
 precocious, 78
- Adrenergic blocking agents, in hypertension
 with pregnancy, 636-638
- Age, maternal
 and fetal chromosome abnormalities, 332
 and outcome of pregnancy, 1217-1220
- Alcohol
 injections in pruritus of vulva, 1102
 intravenous, in management of premature
 labor, 535-537
 maternal ingestion of, affecting newborn,
 307
- Alcoholism, and impotence, 230, 231
- Aldosterone antagonists, in hypertension with
 pregnancy, 640
- Alkalosis, fetal, secondary, 581
- Allergy, and contact dermatitis of vulva,
 1002-1004
- Alpha fetoprotein. *See* α -Fetoprotein
- Alphaprodine, in labor, 497
- Amebiasis, smears in, 971
- Amenorrhea
 and hyperprolactinemia, 129-133
 in polycystic ovarian disease, 99
 primary, and delayed puberty, 81-84
- Amiloride, in hypertension with pregnancy,
 640
- Amino acids
 in amniotic fluid, 303
 intraamniotic infusions of, 306-307
 serum levels in pregnancy, 301
 relation to infant growth, 305
- Ammonium chloride therapy, in hypertension
 with pregnancy, 640
- Amniocentesis, 330
 indications for, 336
 preparation for, 336-337
- Amniocentesis (*continued*)
 technique of, 337-339
 ultrasound with, 322-323, 337-338
 bladder fullness affecting, 323, 338
- Amniography, 330
- Amniotic fluid
 amino acid infusions in, 306-307
 amino acid levels in, 303
 analysis in hypertension with pregnancy,
 631
 antibacterial mechanisms in, 458-459
 embolism of, and fibrinogen degradation
 products in serum, 348
 in fetal maturity evaluation, 550
 lecithin/sphingomyelin ratio in, 553-555
 in infants of diabetics, 450
 and meconium aspiration syndrome, 605
 proteins in, 301-302
- AMP, cyclic, and action of peptide hormones,
 55-57
- Androgens
 conversion to estrogens, 58, 110, 122
 in corpus luteum, 48
 in follicular fluid, 41
 metabolism of, 115-122
 clearance rates in, 118-120
 in fetus and newborn, 120
 in hirsute women, 121-122
 production in normal females, 116-117
 serum levels of
 in childhood, 1144
 in polycystic ovarian disease, 100-102
 synthesis from cholesterol, 58
- Androstenedione, production in normal
 females, 116
- Anemia, autoimmune hemolytic, in
 pregnancy, 390
- Anencephaly
 and estril levels in plasma, 360
 ultrasound in prenatal diagnosis of, 315
- Anesthesia, obstetric, 489-509
 in abortion in teenagers, 1181-1183
 in breech presentation, 525
 caudal epidural, 501
 in cesarean section, 504-508
 general anesthesia, 507-508
 local technique, 504-505
 regional techniques, 505-507
 inhalation anesthetics in, 504
 in labor, 494-504
 local anesthetics in, 498-504
 lumbar epidural, 498-500
 paracervical block in, 501-503
 psychophysical methods, 495-496
 pudendal block in, 503-504

- Anesthesia (*continued*)
 safety aspects in, 492-494
 systemic medications in, 496-498
- Angiography, renal, in pregnancy, 940
- Angiomyolipoma, in pregnancy, 919
- Angiotensin II, sensitivity to, and prediction of pregnancy-induced hypertension, 403
- Anovulation, 87-95
 bromocriptine in, 135, 160
 in chromosomal or genetic defects, 88-90
 in hypothalamic defects, 93-95
 and induction of ovulation, 147-161
 in ovarian defects, 88-91
 in pituitary defects, 91-93
 in polycystic ovarian disease, 99-112
 pathophysiology of, 106-108
- Antibiotics, prophylactic
 in cesarean section, 472-473
 in rheumatic heart disease, 432
- Antibody tests, in pregnancy with urinary tract infections, 944
- Anticoagulants, in pregnancy, affecting fetus, 433
- Antihypertensive agents
 affecting renin production, 645
 contraindications to, 645
 in preeclampsia-eclampsia, 892-893
 in pregnancy, 635-645
- Aortic coarctation, in pregnancy, 434-435
- Apgar scores
 breech presentation affecting, 523, 527
 and fetal heart rate patterns, 574
- Arachidonic acid, and premature labor, 535
- Aromatase
 activity in granulosa cells, 41
 and estrogen synthesis, 58
- Arthritis, rheumatoid, in pregnancy, 385-386, 900
- Ascites, fetal, ultrasonic diagnosis of, 319-320
- Asphyxia, fetal, in breech presentations, 520, 523
- Aspiration, placental, 330
- Aspirin, in management of premature labor, 539
- Atrophic disorders, of vulva, 1032
- Autoimmune disorders, in pregnancy, 385-393
- Bacterial infections in pregnancy, 455-473
 in abortions, 461-462
 and antibacterial mechanisms in amniotic fluid, 458-459
 and cervical protective barrier, 457
 from Group B beta hemolytic streptococcus, 466-467
- Bacterial infections (*continued*)
 host defense mechanisms in, 455-459
 in premature rupture of membranes, 462-466
 and puerperal sepsis, 467-473
 and transplacental passage of infectious agents, 459-460
 urinary tract infections, 422-424
- Bacteriuria, in pregnancy, 422-424, 870-871, 879, 921-926
 in diabetics, 923
 diagnosis of, 924-925, 943-944
 management of, 925-926
- Barbiturates, in labor, 496-497
- Bartholine cyst and abscess
 marsupialization in, 966, 975-977
 Word catheter in, 973, 977
- BCG vaccine. *See* Immunotherapy
- Behcet syndrome, estrogen therapy in, 987
- Bendroflumethiazide, in hypertension with pregnancy, 640
- Benzthiazide, in hypertension with pregnancy, 640
- Betadine, in vulvar lesions, 983-984
- Bicarbonate, reabsorption in kidney, 851-852
- Biopsy
 renal, in pregnancy, 416-418
 in vulvar diseases, 966
- Birth control. *See* Contraceptives
- Birth weight
 and breech presentations, 516
 maternal nutrition affecting, 306
 and maternal weight gain, 305
 in premature infants, 542
- Bladder. *See also* Detrusor muscle
 anatomy of, 824-825
 cystometry of. *See* Cystometry
 diseases with urinary incontinence, 734
 dyssynergia of, 675, 677-678, 742-743
 embryology of, 823-824
 fullness of, affecting amniocentesis, 323, 338
 hypotonic, 674-675
 innervation of, 830
 neck closure patterns in, 740-743
 neural control of function, 653-667
 neurogenic, 701, 743, 744
 partial denervation for detrusor dyssynergia, 797-805
 in pregnancy, 869, 908
 pressure studies in incontinence, 690-691, 714
 rotational descent of neck, 759, 761-762
 rupture in pregnancy, 918
 sensation of fullness in, 690
 vesicoureteral junction anatomy, 863-865

Blood

- changes in preeclampsia-eclampsia, 885
- studies in vulvar disease, 968-969

Blood pressure

- in females, 620
- in pregnancy, 413, 431. *See also*

Hypertension

Blood vessels, in preeclampsia-eclampsia, 884

Blood volume

- hypovolemia in newborn, 601
- in pregnancy, 413-414, 431

Boils, vulvar, 1001

Bowen's disease, compared to condyloma acuminatum, 1069-1070

Bowman's capsule, 828

Brain

- estrogen receptors in, 22
- and neural control of urethrovaginal function, 653-658
- in preeclampsia-eclampsia, 885

Breast

- cancer of, mammographic screening in, 1-13
- development in puberty, 1140-1142

Breech presentation, 511-531

- anesthesia in, 525
- cesarean section in, 516, 527-529
- and congenital abnormalities, 519-520
- diagnosis of, 513-514
- etiology of, 512-513
- fetal asphyxia in, 520, 523
- and growth retardation, 516-519
- and management of abnormalities, 515-516
- maneuvers in, 516
- morbidity from, 523-525
- mortality from, 521-523
- obstetric complications with, 520
- in prematurity, 512, 516, 525
- and selection of delivery method, 526-530
- vaginal delivery in, 527
- version in, 525-526

Bromocriptine

- and ovulation induction, 160
- and prolactin levels, 135, 160

Bullous diseases of vulva, 1007-1021

Bupivacaine, in labor, 498

Burow's solution, in vulvar lesions, 983

Calcium

- intake in adolescent pregnancy, 1206
- and myometrial contractions, 140-141

Calculi, urinary, in pregnancy, 420, 912-914, 927-928

Calories

- expenditure in pregnancy, 298
- in adolescence, 1205

Calories (*continued*)

supplementation in pregnancy, 306-307

Candidiasis, of vulva, 998-999, 1033, 1035

culture specimens in, 970

gentian violet in, 973, 983

scrapings of material in, 971

smears in, 970

Carbonic anhydrase inhibitors, in

hypertension with pregnancy, 640

Carbuncles, of vulva, 1001

Carcinoma. *See* Tumors

Cardiomyopathy, in pregnancy, 440

Cardiotachometer, in fetal heart rate monitoring, 564-565

Cardiovascular disease in pregnancy, 429-440

cardiomyopathy, 440

coarctation of aorta, 434-435

Eisenmenger syndrome, 437

guidelines in management of, 431-434

Marfan's syndrome, 435-436, 900

mitral stenosis, 439-440

and prosthetic heart valves, 438-439

pulmonary hypertension, 437-438

surgery in, 433-434

tetralogy of Fallot, 436-437

Catheterization

intrauterine, 569

urinary, in pregnancy, 895

Caustic therapy, in condyloma acuminatum, 1070-1071

Cellulitis, of vulva, 1001

Cephalopelvic disproportion, and breech presentation, 527

Cesarean section

anesthesia in, 504-508

in breech presentation, 516, 527-529

in herpes simplex infection, 478

and incidence of infections, 467-473

prophylactic antibiotics in, 472-473

Chancere, in syphilis, 2048-2049

Chancroid, 1046-1047

clinical aspects of, 1046-1047

diagnosis of, 1047

intralesional test in, 971

smears in, 970, 971

treatment of, 1047

Chemotherapy

in condyloma acuminatum, 1072

in melanoma, 1126

in vulvar diseases, 987-988

Chickenpox, in pregnancy, 480-482

Childhood. *See also* Adolescence; Newborn

endocrine development in, 69, 1143

prolactin levels in, 128

Chlamydia infections

- Chlamydia infections (*continued*)
 and characteristics of organisms, 1043-1044
 serologic tests for, 969
- 2-Chloroprocaine, in labor, 498
- Chloroquine, in lichen sclerosus of vulva, 1104
- Chlorothiazide, in hypertension with pregnancy, 640
- Cholesterol, and steroidogenesis, 58
- Chromosome studies, 331-336
 abnormalities in, 332-336
 and anovulation, 88-90
 parents as carriers of, 333-334
 in Down's syndrome, 331, 333-334
 normal karyotypes in, 331, 332
- Clitoris
 hood adhesions in, and sexual problems, 195
 and sexual responses, 184, 187, 193, 198
- Clomiphene, and ovulation induction, 149, 153-156, 159
- Clonidine, in hypertension with pregnancy, 637
- Coarctation of aorta, in pregnancy, 434-435
- Coitus, painful. *See* Dyspareunia
- Collagen diseases, in pregnancy, 899-901
- Colpocystourethrography, 725-735
- Condyloma
 acuminatum, 1061-1076
 antibody formation in, 1064
 caustic therapy in, 1070-1071
 chemotherapy in, 1072
 clinical course of, 1067-1068
 diagnosis of, 1069-1070
 electrosurgery in, 977
 etiology of, 1061-1062
 5-fluorouracil in, 988
 giant, of Bushke and Lowenstein, 1066-1067
 immunology of, 1062-1064
 incidence of, 1064-1065
 malignancy related to, 1065-1066
 podophyllin in, 987, 1070-1071
 surgery in, 1072
 treatment of, 1070-1076
 vaccine therapy in, 988, 1063-1064, 1072-1076
 latum, of vulva, 1033, 1036
- Congenital abnormalities
 and breech presentations, 519-520
 and chromosome abnormalities, 322-336
 prenatal diagnosis of. *See* Prenatal diagnosis
- Contraceptive services, lack of, and adolescent pregnancies, 1155-1156
- Contraceptives
 Contraceptives (*continued*)
 affecting sexual response, 197-198
 choice of, in young women, 246-248
 use in adolescence, 1163, 1200, 1208-1212
- Contractions, uterine, monitoring in labor, 569-571
- Copper deficiency, in pregnancy, 308
- Corpus luteum, 48-51
- Corticosteroids
 fetal production of, and premature labor, 534
 therapy with
 affecting fetus, 388, 466
 and lung maturation in infants, 466, 542, 557-558
 in pemphigus, 1010
 in vulvar diseases, 986-987, 1101
- Counseling, 163-277
 and abortion in teenagers, 1179-1180
 active listening in, 168
 and attitude of acceptance, 169
 case reports of, 167, 170, 171
 for couples, 249-257
 and analysis and management of problems, 251-255
 community resources for, 257
 and health promotion, 256
 and prevention of problems, 256
- diagnostic process in, 167-170
 and doctor-patient relationships, 173-180
 embarrassment in, 172
 expressions of anger in, 171
 of formerly married, 259-266
 and alleviation of guilt, 264-265
 case reports of, 262, 263, 264, 265, 266
 and changes in lifestyle, 265-266
 goals in, 259-262
 identification of needs in, 263-264
 initial steps in, 262-263
 loneliness in, 260
 personal relationships in, 266
 and relationships with friends, 260-261
 sex roles in, 261-262
 initial request for, 166-167
 problems in, 170-172
 reactions in, 169-170
 reassurance in, 171
 in sexual problems, 191-202
 and changing of attitudes and feelings, 199-200
 and communication between partners, 199
 and contraception prescription, 197-198
 and diagnosis and treatment of pathology, 194-197

Counseling, in sexual (*continued*)

- in dyspareunia, 186, 189, 194, 205-217
- education in, 192-194
- and guidelines for referrals, 200-201
- history-taking in, 183-190
- in impotence, 228-233
- and masturbation, 198-199
- physical examination in, 197
- postmenopausal, 269-277
- in premature ejaculation, 223-228
- preventive measures in, 201-202
- reading material in, 198
- in vaginismus, 186, 189, 195, 218-220
- for sexually active young women, 235-248
 - and attitudes of patient, 237-238
 - and attitudes of physician, 236-237
 - and contraception choice, 246-248
 - and dealing with problems of patient, 242-246
 - history-taking in, 238-240
 - pelvic examination in, 240-242
 - time factors in, 170
 - understanding as factor in, 168-169
 - unrealistic expectations in, 172

Cramps, menstrual. *See* Dysmenorrhea

Creatinine

- in amniotic fluid, and fetal maturity, 550
- clearance test
 - in pregnancy, 628
 - in renal disease, 406
- serum levels in renal disease, 415

Crotamiton, antipruritic effects of, 987

Cryosurgery

- in condyloma acuminatum, 1072
- in vulvar diseases, 979-980

Culture specimens, in vulvar disease, 969-970

Curettage, in vulvar diseases, 965-966

Cushing's disease, hyperprolactinemia in, 132

Cutaneous vulvar conditions

- infections, 957-958, 996-1002
- inflammations, 991-996

Cyst

Bartholin's

- marsupialization in, 966, 975-977
- Word catheter in, 973, 977
- pelvic, ultrasonic diagnosis in pregnancy, 326
- polycystic ovarian disease, 99-112
- polycystic renal disease in pregnancy, 420

Cystocele, and urinary incontinence, 759-773

Cystography, in pregnancy, 939

Cystometry

- direct electronic, 695-703
- gas, 679-683, 713

Cystometry (*continued*)

and metallic bead-chain

- urethrocytography, 725-735, 778, 789-790
- postpartum, 867-869
- standard water, 669-671, 790-791
- videocystourethrography, 715-720

Cytogenetics, 331-336

Cytologic studies, in vulvar disease, 967

Cytomegalovirus infection, in pregnancy, 479-480

Death in utero

- and α -fetoprotein levels, 345
- and misdiagnosis of FHR, 564
- and placental lactogen levels, 369
- ultrasonic diagnosis of, 321-322

Dehydroepiandrosterone

- clearance studies in hypertension with pregnancy, 633
- loading tests in pregnancy, 360
- in hypertension, 632
- plasma levels in childhood, 1143
- production in normal females, 116

Dermatitis of vulva

- contact, 1002-1004
- herpetiformis, 1019, 1020
- neurodermatitis, 995-996
- seborrheic, 994

Dessication surgery, in condylomata acuminata, 978

Detrusor muscle, 666

- activity in urinary incontinence, 673-678, 685-690, 699-701
- cystometric studies of function. *See*

Cystometry

- dyssynergia of, 675, 677-678, 742-743
- partial bladder denervation for, 797-805
- innervation of, 662-665
- uninhibited contraction of, 676-677
- volitional suppression of reflex in, 687

Dexamethasone with clomiphene, for ovulation induction, 156

Diabetes

- and impotence, 230
- in pregnancy, 443-451, 899
 - bacteriuria in, 923
 - classification of, 445-446
 - delivery in, 451
 - detection and diagnosis of, 446-447
 - and estriol analysis, 356, 360
 - management of, 447-451
 - and maternal morbidity and mortality, 445
 - and maturation of fetal lungs, 450, 556

- Diabetes, in pregnancy (*continued*)
 pathophysiology of, 444
 and perinatal morbidity and mortality, 444-445
 placental lactogen levels in, 364, 368
 renal function in, 420
 and ultrasonic studies of fetus, 320
- Diazepam, in labor, 497
- Diazoxide, in hypertension with pregnancy, 638
- Dichlorphenamide, in hypertension with pregnancy, 640
- Diet. *See* Nutrition
- Diethylstilbestrol, maternal use of, and counseling of daughters, 246
- Diuretics
 in hypertension with pregnancy, 640-644
 in preeclampsia-eclampsia, 893
 in pregnancy, affecting fetus, 433
- Diverticula, urethral, 752-753
- Divorced persons, counseling of, 259-266
- Donovan bodies, smears for identification of, 971
- Douching procedures, 242
- Down's syndrome, chromosome pattern in, 331, 333-334
- Drug-induced conditions, and sexual problems, 195, 232
- DTIC therapy, in melanoma, 1126
- Duchenne's muscular dystrophy, prenatal diagnosis of, 330, 335
- Duodenal atresia, ultrasound in prenatal diagnosis of, 319
- Dye-light therapy, in vulvar herpes, 984
- Dysmenorrhea, 139-144, 242-243
 characteristics of, 139
 pathophysiology of, 139-141
 treatment of, 141-144
- Dyspareunia, 186, 189, 194, 205-217
 counseling in, 245
 definition of, 205-206
 etiology of, 206-212
 Kegel's exercises in, 214, 215-216
 management of, 212-217
 organic factors in, 208-210
 postmenopausal, 275
 psychogenic factors in, 210-212
 management of, 212-214
 vaginal self-dilation methods in, 215-217
- Dysplasia, of vulva, 1087-1090
- Dystrophies, vulvar, 1025-1029, 1081-1104
- Eclampsia. *See* Preeclampsia-eclampsia
- Ecchyma, of vulva, 1001
- Edema, in preeclampsia-eclampsia, 886
- Educational programs
 failures of, and adolescent pregnancies, 1154-1155
 for family life, in adolescence, 1154, 1200-1202
- Ehlers-Danlos syndrome, in pregnancy, 900
- Eisenmenger syndrome, pregnancy in, 437
- Ejaculation
 premature, 223-228
 etiology of, 225-226
 therapy of, 226-228
 retrograde, 230
 from phenothiazines, 227, 232
- Electrocardiography of fetal heart rate
 abdominal wall approach in, 567-568
 direct technique in, 563-566
- Electromyography, of urethral sphincter, 672-673, 683-684, 720-721
- Electrosurgery, in vulvar diseases, 977-978
- Embolism, amniotic fluid, and fibrinogen degradation products in serum, 348
- Emotional factors. *See* Psychogenic factors
- Empty sella syndrome, anovulation in, 93
- Encephalitis, Venezuelan equine, in pregnancy, 483-484
- Endocrinology, 15-161
 action of reproductive hormones, 53-66
 androgen metabolism, 115-122
 anovulation, 87-95
 dysmenorrhea, 139-144
 menstrual cycle regulation, 17-28
 ovarian function, 31-51
 in adolescence, 1144
 ovulation induction, 147-161
 polycystic ovarian disease, 99-112
 prolactin metabolism, 125-135
 pubertal development, 67-85, 1143-1144
- Energy requirements, in pregnancy, 298-299
 in adolescence, 1205
- Erosions, vulvar, 959-960
- Erysipelas, of vulva, 1001
- Erythema multiforme, of vulva, 1017-1019, 1020
- Erythrasma, of vulva, 999-1000
 scrapings of material in, 971
 Wood's light studies in, 968
- Erythroblastosis fetalis, management of, 606
- Estriol analysis in pregnancy, 353-361
 and dehydroepiandrosterone sulfate-loading tests, 360-361
 serum, 357-360
 urinary, 355-357
 in diabetes, 356
 in fetal growth retardation, 356
 in hypertension, 356-357

- Estriol analysis, urinary (*continued*)
 in postmaturity, 356
- Estrogens
 and central nervous system function, 22-23
 in corpus luteum, 48
 deficiency of
 and sexual problems, 195
 and urinary incontinence, 747, 749, 762
 and ovulation induction, 149, 154-156
 postmenopausal use of, 275-277
 and premature labor, 534
 production from androgens, 58, 110, 122
 and prolactin levels, 127, 133
 receptors for
 in brain tissue, 22
 in ovarian cells, 34
 serum levels of, 74
 in hypertension with pregnancy, 632
 in polycystic ovarian disease, 102-104
 in puberty, 1144
 as therapy in vulvar diseases, 987, 1104
 "two cell" theory of synthesis of, 44, 58
- Ethacrynic acid, in hypertension with pregnancy, 641
- Ethanol. *See* Alcohol
- Examination
 pelvic, in sexually active young women, 240-242
 premarital, new approach to, 255-256
- Excision, of vulvar lesions, 966, 973-975
- Expectations, unrealistic
 and changes in lifestyle, 266
 in counseling, 172
 and sexual problems, 186, 189
- Fallot's tetralogy, pregnancy in, 436-437
- Family life, education for, in adolescence, 1154, 1200-1202
- Family relationships, and adolescent pregnancies, 1163-1164
- Females. *See* Women
- α -Fetoprotein assay, 330, 342-346
 in absence of fetus, 346
 abortion affecting, 344
 in complications of pregnancy, 345
 fetal death affecting, 345
 in multiple gestation, 345
 in Rh disease, 345
- Fetoscopy, 330
- Fetus
 acidosis of
 primary, during hypoxia, 579-580
 secondary, 581
 agents affecting
 anticoagulants, 433
- Fetus, agents affecting (*continued*)
 corticosteroids, 388, 466
 diuretics, 433
 alkalosis of, secondary, 581
 androgen metabolism in, 120
 biparietal diameter of, 312
 cephalopelvic disproportion, and breech presentation, 527
 death in utero. *See* Death in utero
 endocrine development in, 67-69
 growth retardation in. *See* Growth retardation
 heart rate monitoring in, 375-383, 561-576.
 See also Heart rate monitoring
 maternal diseases affecting
 cytomegalovirus, 480
 diabetes, 444
 herpes, 477-479, 1016, 1057
 streptococcal infections, 466-467
 varicella, 481
 maturation evaluation, 547-558
 amniotic fluid measurements in, 550
 biochemical measurements in, 549
 bubble stability test in, 554
 and creatinine in amniotic fluid, 550
 and lecithin/sphingomyelin ratio in amniotic fluid, 450, 553-555
 and lung development, 550-557. *See also* Lung development
 Nile blue sulfate test in, 550
 radiology in, 549
 ultrasound in, 312, 549
 nutritional needs of, 297-309
 and effects of dietary deficiency, 303-305
 and effects of dietary supplementation, 306-307
 prenatal diagnosis of disorders. *See* Prenatal diagnosis
 protein synthesis in, 300-301
 scalp blood analysis, 582-585
 oxygen values in, 589-590
 ultrasonic studies of, 311-322, 330. *See also* Ultrasound in obstetrics
- Fibrinogen, degradation products measured in pregnancy, 347-350
 in eclampsia, 348-349
 in preeclampsia, 349-350
- Fluid and electrolyte therapy, in preeclampsia-eclampsia, 891
- Flumethiazide, in hypertension with pregnancy, 640
- Fluorescence studies, with Wood's light, in vulvar disease, 968
- 5-Fluorouracil
 in condyloma acuminatum, 1072

- 5-Fluorouracil (*continued*)
in vulvar diseases, 988
- Follicle development, ovarian, 31-44
- Follicle-stimulating hormone
action of, 54-60
and aromatase activity in granulosa cells, 41
in fetal circulation, 67
in follicular fluid, 40
formation of, 25
and induction of LH receptors, 42
receptors in granulosa cells, 32-34
serum levels of, 74
in infancy and childhood, 69
in polycystic ovarian disease, 104-106
in puberty, 1145
- Follicular fluid
formation of, 36-41
hormones in, 40-41
plasminogen in, 47-48
- Folliculitis, of vulva, 1001
- Fox-Fordyce disease, estrogen therapy in, 987
- Freckle, Hutchinson's, 1120
- Frei skin test, in lymphogranuloma venereum, 971
- Friends of formerly married persons,
relationships with, 260-261
- Fulguration, in condylomata acuminata, 978
- Furosemide, in hypertension with pregnancy, 641
- Furuncles, of vulva, 1001
- Galactorrhea, and hyperprolactinemia, 129-133
- Ganglionic blocking agents, in hypertension with pregnancy, 644
- Gastrointestinal lesions, ultrasound in prenatal diagnosis of, 319
- Genetic disorders, prenatal diagnosis of, 329-339
and counseling of parents, 336-337
- Gentian violet, in candidiasis of vulva, 973, 983
- Glomerular filtration rate, 846
in pregnancy, 412-413, 856, 938
in renal disease, 414
- Glomerulonephritis, in pregnancy, 418-419, 879-880, 896-898
- Glucose
metabolism in pregnancy, 443-444
serum levels of, and placental lactogen secretion, 364
- Glucosuria, in pregnancy, 856, 899
- Glycoprotein levels in pregnancy
 α -2-glycoprotein, 347
- Glycoprotein (*continued*)
 β -1-glycoprotein, 346
- Goltz's syndrome, 1070
- Gonadotropins
human chorionic, 25, 54
and ovulation induction, 149, 153-154, 156-159
human menopausal, and ovulation induction, 149, 156-159
pituitary, 54. *See also* Follicle-stimulating hormone; Luteinizing hormone
composition of, 25
metabolism of, 25-27
and ovarian cycle, 24-25
in polycystic ovarian disease, 104-106
secretion in childhood, 69, 1145
serum levels of, 25-27, 74
- Gonorrhea
counseling in, 244
culture specimens in, 969
smears in, 970
- Granuloma inguinale, 1041-1043
clinical aspects of, 1042-1043
diagnosis of, 1043
smears in, 971
treatment of, 1043
- Granulosa cells
aromatase activity in, 41
gap junctions in, 35-36
luteinized, 48
receptors in, 32-35, 42
- Group sessions
premarital, 255-256
and relational health promotion, 256
- Growth patterns, in puberty, 1137-1140
- Growth retardation, intrauterine
and breech presentations, 516-519
and estriol analysis
in plasma, 360
in urine, 356
in hypertension, 399
in malnutrition, 303-307
placental lactogen levels in, 367-368
ultrasonic recognition of, 312-313
- Guancydine, in hypertension with pregnancy, 638
- Guanethidine, in hypertension with pregnancy, 637
- Guilt
alleviation of, in formerly married persons, 264-265
sexual, 186
- Gynecologists. *See* Physicians
- Gynecomastia, and hyperprolactinemia, 133

- Hailey-Hailey syndrome, 1011, 1020, 1036
- Health care for women, changing attitudes in, 173-180
- Health promotion, relational, 256
- Heart
- diseases in pregnancy, 429-440. *See also* Cardiovascular disease
 - in preeclampsia-eclampsia, 885
 - valvular prostheses, pregnancy risks with, 438-439
- Heart rate monitoring, fetal, 375-383, 561-576
- acceleration patterns in, 573
 - baseline in, 572-573
 - classification of patterns and pathophysiology of, 571-572
 - contraction stress test in, 376, 377-378
 - combined with non-stress test, 379-383
 - and death in utero, 564
 - deceleration patterns in, 573-574
 - direct technique for, 563-566
 - effect on perinatal outcome, 574-576
 - electrocardiography in
 - abdominal wall, 567-568
 - direct, 563-566
 - in hypertension with pregnancy, 633-634
 - indirect techniques in, 566-568
 - instrumentation in, 561-562
 - non-stress testing in, 376, 378-379
 - combined with contraction stress test, 379-383
 - periodic FHR in, 573-574
 - phonocardiography in, 567
 - ultrasonography in, 566-567
 - and uterine activity display, 566
- Hemolytic anemia, autoimmune, in pregnancy, 390
- Hemolytic disease of newborn, management of, 606
- Hemophilia A, prenatal diagnosis of, 335
- Haemophilus ducreyi*, smears for identification of, 970
- Henle's loop, 828
- Hepatitis B infection, in pregnancy, 482-483
- Herpesvirus infections
- of newborn, 478, 1057-1058
 - in pregnancy, 1015-1017
 - herpes simplex, 477-479
 - herpes zoster, 480-482
 - of vulva, 1053-1059
 - betadine in, 983-984
 - and carcinoma, 1058
 - clinical aspects of, 1056-1057
 - culture specimens in, 970
 - dye-light therapy in, 984
 - laboratory studies in, 1055
- Herpesvirus, of vulva (*continued*)
- laser therapy in, 981-982
 - perinatal aspects of, 1057-1058
 - recurrent, 1057
 - serologic tests for, 969
 - smears in, 971
 - therapeutic considerations in, 1058-1059
- High-risk pregnancy
- and autoimmune disorders, 385-393
 - blood protein levels in, 341-350
 - cardiac diseases in, 429-440
 - diabetes in, 443-451
 - estriol analysis in, 353-361
 - fetal heart rate monitoring in, 375-383, 561-576
 - and management of hypertension, 397-408
 - placental lactogen levels in, 363-371
 - and prenatal risk assessment, 287-294. *See also* Prenatal diagnosis
 - renal disease in, 414-425
 - and role of pediatrician, 593-606
- Hirsutism
- androgen metabolism in, 121-122
 - in heterosexual precocity, 79
 - in polycystic ovarian disease, 99, 122
- History-taking
- and counseling of sexually active young women, 238-240
 - in sex counseling, 183-190
- Hormone therapy, in vulvar diseases, 984-987
- Hormones, reproductive, 53-66
- peptides, 54-60
 - steroids, 61-66
- Hurler's syndrome, in pregnancy, 900
- Hutchinson's freckle, 1120
- Hyaline membrane disease, and fetal lung maturation. *See* Lung development in fetus
- Hydralazine
- in hypertension with pregnancy, 401, 638
 - in preeclampsia-eclampsia, 892-893
- Hydramnios, fluffy fetus with, 320
- Hydrocephalus, ultrasound in prenatal diagnosis of, 315
- Hydrochlorothiazide, in hypertension with pregnancy, 640
- Hydrogen ion secretion, in kidney, 851-852
- Hydronephrosis, ultrasound in prenatal diagnosis of, 319
- Hydroureter, in pregnancy, 857-861
- Hydroxyprogesterone caproate, in management of premature labor, 537
- Hymeneal strand, and sexual problems, 196
- Hyperparathyroidism, in pregnancy, 914

Hypertension in pregnancy, 397-408, 619-646, 881-882

- adrenergic blocking agents in, 636-638
- ambulatory care in, 403
- amniotic fluid analysis in, 631
- arteriolar dilators in, 638-639
- blood chemistry in, 629-630
- cardiovascular studies in, 627-628
- characteristics of, 624
- classification of, 620-622
- control of blood pressure in, 401
- dehydroepiandrosterone loading studies in, 632
- dehydroepiandrosterone sulfate clearance studies in, 633
- diuretics in, 640-644
- endocrine studies in, 629
- and estriol analysis
 - in plasma, 360
 - in urine, 356-357
- estrogen levels in, 632
- and evaluation of fetal-placental unit, 630-634

- and evaluation of patient, 625-630
- fetal heart monitoring in, 633-634
- and fetal lung maturation, 402
- and α -fetoprotein levels, 345
- ganglionic blocking agents in, 644
- hospitalization in, 404-408
- with immature fetus, 398-399
- incidence of, 622-624
- laboratory studies in, 627-630
- with mature infant, 397-398
- physical examination in, 626-627
- placental enzyme studies in, 631-632
- placental lactogen assay in, 366, 633
- and preeclampsia-eclampsia, 886, 889
- prevention of convulsions in, 399-401
- prognosis of, 624-625
- pulmonary hypertension, 437-438
- renovascular studies in, 628-629
- screening tests in prediction of, 403
- social evaluation in, 630
- therapy in, 634-645
- ultrasonography in, 630
- veratrum alkaloids in, 644

Hypertrophic disorders, of vulva, 1033-1037

Hypnosis, for pain relief in labor, 496

Hypogonadism

- hypergonadotropic, 81-83
- hypogonadotropic, 83-84

Hypothalamus

- defects causing anovulation, 93-95
- function in adolescence, 1145-1146
- lesions with hyperprolactinemia, 130-131

Hypothalamus (*continued*)

- release of LHRH, 21-22, 54

Hypothermia in newborn, management of, 602-603

Hypothyroidism

- hyperprolactinemia in, 132
- and precocious puberty, 77

Hypoxia, and fetal acidosis, 579-580

Immune serum globulin

- in hepatitis B, 483
- in varicella, 482

Immunofluorescence studies

- in dermatitis herpetiformis, 1019
- in herpes gestationis, 1016-1017
- in pemphigoid of vulva, 1013, 1015
- in pemphigus, 1010
- in vulvar bullous disease, 966-967

Immunology

- and autoimmune disorders, 385-393
- and condyloma acuminatum, 1062-1064
- and host defense mechanisms in pregnancy, 455-456
- and maternal transmission of IgG, 300

Immunotherapy

- in condyloma acuminatum, 1063-1064, 1072-1076
- in melanoma, 1126-1127
- in vulvar diseases, 988

Impetigo, of vulva, 1001

Impotence, 228-233

- physical causes of, 229-232
- prosthetic implants in, 233
- psychogenic causes of, 229, 232-233

Incontinence, urinary, 649-815. *See also*

Urinary incontinence

Indomethacin, in management of premature labor, 539

Infections in pregnancy

- bacterial, 455-473
- urinary tract, 422-424
- viral, 477-486

Infertility, anovulatory. *See* Anovulation

Insulin therapy, in diabetes in pregnancy, 449

Intertrigo, of vulva, 1033

Intubation, tracheal, of newborn, 598-600

Iron

- dietary requirements in pregnancy, 308
- in adolescence, 1206
- therapy in pregnancy, 432

Isoxsuprine, in management of premature labor, 538

Kallman's syndrome, anovulation in, 94

Karyotypes, normal, 331, 332

- Kegel's exercises, in dyspareunia, 214, 215-216
- Keratinocytes, 1118
- 17-Ketosteroids, urinary, in childhood, 1143
- Kidney
 and acid-base homeostasis, 851-852
 acute failure in pregnancy, 421-422, 875-877, 901-904
 agenesis of
 bilateral, 832-833
 unilateral, 833-834
 anatomy of, 825-826, 828
 anomalies of, 832-842
 blood flow in, 845
 in pregnancy, 939
 blood supply of, 826-827
 disorders in pregnancy, 414-425, 875-880, 894-904
 biopsy in, 416-418
 in diabetes, 420
 diagnostic tests in, 937-944
 fetal surveillance in, 418
 function tests in, 416
 maternal surveillance in, 416-418
 pathophysiology of, 414-415
 ectopia of, 839
 crossed, 840
 embryology of, 819-822, 831-832
 function tests, 937-939
 in pregnancy, 416
 fused, pelvic, 839-840
 glomerular filtration in, 846
 in pregnancy, 412-413, 856, 938
 glomerulonephritis in pregnancy, 418-419, 879-880, 896-898
 horseshoe, 841-842
 hypoplasia of
 dysplastic, 836
 unilateral, 834-836
 innervation of, 828
 lupus nephritis in pregnancy, 387, 419
 nephrotic syndrome in pregnancy, 419-420, 879, 898-899
 polycystic disease in pregnancy, 420
 postpartum renal failure, 422
 potassium handling in, 850-851
 in preeclampsia, 877-878, 884, 889-890
 in pregnancy, 411-414, 855-857, 907-908
 single, with double pelvis, 837-839
 sodium handling in, 848-850
 supernumerary, 839
 transplantation of, pregnancy after, 421, 931-934
 trauma in pregnancy, 918
 tuberculosis in pregnancy, 420, 895-896
- Kidney (*continued*)
 tubular function in pregnancy, 413
 ultrasound in prenatal diagnosis of lesions, 319
 urine concentration and dilution in, 846-848
 in pregnancy, 939
 urolithiasis in pregnancy, 420, 912-914, 927-928
- Koebner phenomenon, in lichen planus, 993
- Kraurosis vulvae. *See* Lichen sclerosis of vulva
- Labor
 anesthesia in, 489-504
 breech presentation in, 511-531
 cardiovascular alterations in, 431
 in diabetes, 451
 management in hypertension, 401-403
 monitoring in
 of fetal heart rate, 375-383, 561-576
 of uterine activity, 569-571
 pain in, 491-492
 premature, management of, 533-542
 and role of pediatrician, 596-603
- Lactogen, placental, 363-371
 assay in hypertension with pregnancy, 366, 633
 function of, 363-364
 serum levels of, 364-370
 in diabetes, 364, 368
 factors affecting, 364-365
 in fetal anomalies, 369
 in fetal death, 369
 in fetal growth retardation, 367-368
 for gestational dating, 366
 and management of high risk pregnancies, 370
 in postmaturity syndrome, 368-369
 in threatened abortions, 365-366
 in toxemia and hypertension, 366
- Laminaria tents, for abortion in teenagers, 1185-1187
- Laser therapy
 in condyloma acuminatum, 981, 1072
 in vulvar diseases, 980-982
- Laurence-Moon-Biedl syndrome, anovulation in, 94
- Lecithin/sphingomyelin ratio, in amniotic fluid, 553-555
 in hypertension with pregnancy, 631
 in infants of diabetics, 450
- Legal problems, and abortion in teenagers, 1181
- Leiomyoma, uterine, ultrasonic diagnosis in pregnancy, 326
- Lentigo maligna, 1120

- Leriche syndrome, impotence in, 230
- Leukoplakia, vulvar, 1081. *See also* Vulva, white lesions of
- Libido, in menopause, 270
- Lichen
- planus, of vulva, 993-994, 1029
 - sclerosus, of vulva, 1025-1028, 1090-1095
 - in children, 1104
 - with epithelial hyperplasia, 1095
 - laser therapy in, 981
 - testosterone propionate ointment in, 984-986
 - treatment of, 1101-1102
 - simplex chronicus, of vulva, 995-996, 1033, 1035, 1083
- Lifestyle changes, in formerly married persons, 265-266
- Listening, and counseling, 168
- in sexual problems, 192
- Liver, in preeclampsia-eclampsia, 885
- Loneliness, in formerly married persons, 260
- Lung development in fetus, 550-557
- acceleration in, 555-557
 - corticosteroids affecting, 466, 542, 557-558
 - deceleration in, 556
 - in infants of diabetics, 450
 - maternal hypertension affecting, 402
 - and surfactant activity, 552-553
- Lupus erythematosus, in pregnancy, 900
- Lupus nephritis, in pregnancy, 387, 419
- Luteinization, of granulosa cells, 48
- Luteinizing hormone
- action of, 54-60
 - in fetal circulation, 67
 - in follicular fluid, 41
 - mid-cycle surge of, 25, 148
 - receptor induction by FSH, 42
 - releasing hormone
 - action of, 54-60
 - measurements and dynamics of, 23-24
 - and ovulation induction, 159-160
 - release from hypothalamus, 21-22, 54
 - responses to, in polycystic ovarian disease, 105-106
 - serum levels of, 74
 - in infancy and childhood, 69
 - in polycystic ovarian disease, 104-106
 - in puberty, 1145
- Luteolysis, 48-51
- Lymphatics, of urinary system, 830
- Lymphogranuloma venereum, 1043-1046
- clinical aspects of, 1044-1045
 - culture specimens in, 970
 - diagnosis of, 1045
 - Frei skin test in, 971
- Lymphogranuloma venereum (*continued*)
- serologic tests for, 969
 - smears in, 970, 971
 - treatment of, 1046
- Lysozyme in cervical mucus, antibacterial effect of, 457-458
- α -2-Macroglobulin, 347
- Magnesium
- intake in adolescent pregnancy, 1206
 - therapy with vitamin B₆, in dysmenorrhea, 141-142
- Magnesium sulfate therapy
- in hypertension with pregnancy, 399-401
 - in preeclampsia-eclampsia, 892
 - in premature labor, 539
- Male sexual problems, gynecologic implications of, 223-233
- Malnutrition, and fetal growth and development, 303-307
- Mammographic screening, 1-13
- compared to diagnostic evaluation, 2
 - false negatives in, 3-4, 9
 - false positives in, 4, 9
 - guidelines in, 12
 - problems of, 3-11
 - radiation dosage in, 4, 7
 - and self-selection of screeners, 6, 11
- Manganese deficiency, in pregnancy, 308-309
- Mannitol, in hypertension with pregnancy, 640
- Marfan's syndrome, in pregnancy, 435-436, 900
- Marriage
- and counseling of couples, 249-257
 - and counseling of formerly married, 259-266
- Marsupialization, in Bartholin cysts and abscesses, 966, 975-977
- Masturbation, attitudes toward, 198-199
- Maturation of fetus, evaluation of, 547-558
- McCune-Albright syndrome, 77
- Meconium aspiration syndrome, 605
- Melanocytes, 1118
- Melanoma, 1117-1132
- classification of, 1120-1122
 - and cutaneous microanatomy, 1117-1120
 - lentigo malignant, 1120
 - nodular, 1122
 - prognosis of, 1123-1125
 - superficial spreading, 1122
 - treatment of, 1125-1127
 - vulvar, 1127-1131
- Melanosomes, 1118
- Membrane rupture, premature infections in, 462-466

- Membrane rupture (*continued*)
 management of, 539
- Menarche, 72-73, 109, 1142-1143
- Menometrorrhagia, pubertal, 84-85
- Meningomyelocele, ultrasound in prenatal diagnosis of, 317
- Menopause, and sexual problems, 269-277
- Menstrual cramps. *See* Dysmenorrhea
- Menstrual cycle regulation, 17-28
- Meperidine, in labor, 497
- Mercurophyllin, in hypertension with pregnancy, 640
- Mesonephros, 820, 831
- Metabolism, in pregnancy, 443-444
- Metanephros, 821-822, 832
- Methazolamide, in hypertension with pregnancy, 640
- Methyldopa, in hypertension with pregnancy, 637
- Microcephaly, ultrasound in prenatal diagnosis of, 315
- Minoxidil, in hypertension with pregnancy, 638
- Mitral stenosis, pregnancy with, 439-440
- Molar pregnancies, ultrasonic diagnosis of, 323-326
- Molluscum contagiosum, smears in, 971
- Monitoring procedures
 for fetal heart rate, 375-383, 561-576. *See also* Heart rate monitoring
 in labor, logic and editing systems in, 568
 and postpartum infections, 467-473
 and scalp blood analysis in fetus, 582-585
 for uterine activity in labor, 569-571
 catheterization in, intrauterine, 569
 display with fetal heart rate, 566
 tocodynamometry in, 569
- Mortality
 in abortions in adolescence, 1176-1178
 in breech presentations, 521-523
 in diabetes, 444-445
- Multiple gestation
 α -fetoprotein levels in, 345
 lung development in, 555
 placental lactogen levels in, 369
 ultrasonic signs of, 314-315
- Muscular dystrophy, Duchenne type, prenatal diagnosis of, 330, 335
- Myasthenia gravis, in pregnancy, 392-393
- Mycoplasma infections, culture specimens in, 970
- Myoma, uterine, ultrasonic diagnosis in pregnancy, 326
- Myometrium, prostaglandins affecting, 140
- Narcotics, in labor, 497
- Nelson's syndrome, hyperprolactinemia in, 132
- Neonatal conditions. *See* Newborn
- Nephritis, lupus, in pregnancy, 387, 419
- Nephrostomy, percutaneous, 915
- Nephrotic syndrome, in pregnancy, 419-420, 879, 898-899
- Nervous system, central
 defects causing anovulation, 91-95
 and reproductive function, 20-24
- Neural control, of urethrovessical function, 653-667
- Neural tube defects
 and α -fetoprotein levels, 342
 prenatal diagnosis of, 336
- Neurodermatitis, of vulva, 995-996
- Neurologic disorders, impotence in, 231
- Newborn
 androgen metabolism in, 120
 Apgar scores for. *See* Apgar scores
 birthweight of. *See* Birthweight
 cytomegalovirus infection of, 479-480
 hemolytic disease of, 606
 hepatitis B infection of, 482
 herpes infection of, 478, 1057-1058
 hypothermia in, management of, 602-603
 maternal alcohol ingestion affecting, 307
 meconium aspiration syndrome in, 605
 resuscitation of, 597-602
 and role of pediatrician in management, 596-606
 tracheal intubation of, 598-600
 varicella infection of, 481
- Nile blue sulfate test, for fetal maturity, 550
- Nitroprusside, in hypertension with pregnancy, 638
- Nutrition, in pregnancy, 297-309
 in adolescence, 1202-1208
 and amino acid changes, 301
 and amniotic fluid properties, 301-303
 copper deficiency in, 308
 in diabetes, 448, 449
 and effects of dietary deficiency, 303-305
 and effects of dietary supplementation, 306-307
 and energy requirements, 298-299
 in adolescence, 1205
 manganese deficiency in, 308
 in preeclampsia-eclampsia, 891
 and protein changes, 299-301
 trace elements in, 308
 zinc deficiency in, 308

- Obstetricians. *See* Physicians
- Office practice, counseling in. *See* Counseling
- Oocytes, maturation of, 32
- Orgasmic intercourse, frequency in women, 187, 193, 199
- Ovarian function, 31-51
- and corpus luteum development, 48-51
 - defects in anovulation, 88-91
 - and fetal development, 67-69
 - follicle development in, 31-44
 - differentiation in, 32-42
 - and gap junction in granulosa cells, 35-36
 - primary follicles, 32-36
 - primordial growth initiation, 31-32
 - and receptors in granulosa cells, 32-35, 42
 - secondary follicles, 36-42
 - and theca interna development, 36
 - and follicular atresia, 42-44
 - and follicular rupture, 44-47
 - gonadotropins affecting, 24-25
 - in ovulation, 44-48
 - in polycystic disease, 99-112
 - and premature failure, 88
 - prolactin affecting, 27
 - in puberty, 1144
- Ovarian vein syndrome, in pregnancy, 910-912
- Ovulation, 44-48
- and anovulation pathophysiology, 87-95
 - induction of, 147-161
 - agents in, 149, 153-160
 - bromocriptine in, 135, 160
 - clomiphene in, 149, 153-156, 159
 - estrogens in, 149, 154-156
 - hazards in, 151-153
 - human chorionic gonadotropin in, 149, 153-154, 156-159
 - human menopausal gonadotropin in, 149, 156-159
 - long-term residual effects of, 153
 - pretreatment evaluation in, 147
 - releasing hormones in, 159-160
 - therapies approved for use in U.S., 153-159
 - therapies not approved for use in U.S., 159-160
 - treatment plan in, 150-151
 - physiology and pharmacology of, 148-149
- Oxygen
- and fetal acidosis in hypoxia, 579-580
 - and fetal asphyxia in breech presentations, 520, 523
 - values in fetal scalp blood, 689-690
- Oxytocin
- challenge test in fetal heart rate monitoring, 376, 377-378
 - combined with non-stress test, 379-383
 - release of, and premature labor, 534
- Paget's disease of vulva, 1107-1114
- clinical findings in, 1110-1112
 - 5-fluorouracil in, 988
 - histologic findings in, 1112
 - theories for origin of, 1113-1114
- Pain
- in labor, 491-492
 - menstrual. *See* Dysmenorrhea
 - pelvic, in sexually active young women, 245
 - and sexual problems. *See* Dyspareunia
- Papaverine, in hypertension with pregnancy, 638
- Parathyroid gland, and hyperparathyroidism in pregnancy, 914
- Pargyline, in hypertension with pregnancy, 637
- Parkinsonism, hyperprolactinemia in, 132
- Patch testing, in vulvar disease, 968, 1003
- Pediatrician, in management of high-risk pregnancy, 593-606
- in antenatal period, 593-596
 - in intrapartum and immediate neonatal period, 596-603
 - in postpartum period, 603-605
 - special problems in, 605-606
- Pediculosis pubis, diagnosis of, 971
- Pelvic examination, in sexually active young women, 240-242
- Pelvic fracture, in pregnancy, 918
- Pelvic ganglia, and neural control of urethrovesical function, 660-662
- Pelvic relaxation
- and sexual problems, 196
 - and urologic problems, 759-773
- Pemphigoid, of vulva, 967
- benign mucous membrane, 1014-1015, 1020
 - bullous, 1013-1014, 1020
- Pemphigus, of vulva, 1007-1013, 1020
- clinical features of, 1007-1009
 - familial benign chronic, 1011, 1013
 - histology of, 1009-1010
 - immunofluorescence studies in, 1010
 - laboratory findings in, 1009-1010
 - treatment of, 1010
 - vegetans, 1008
 - vulgaris, 967, 1007-1008
- Periarthritis nodosa, in pregnancy, 389-390, 419, 900

- Perinatal medicine, risk assessment in, 287-294
- pH, and maternal-fetal acid-base relationships, 585-589
- Phenothiazines, retrograde ejaculation from, 227, 232
- Phenoxybenzamine, in hypertension with pregnancy, 637
- Pheochromocytoma, in pregnancy, 629
- Phonocardiography, in monitoring of fetal heart rate, 567
- Phospholipids, in amniotic fluid, and fetal maturation evaluation, 550
- Phosphorus intake, in adolescent pregnancy, 1206
- Physicians
 changing relationships with patients, 173-180
 counseling by. *See* Counseling
 pediatricians in management of high-risk pregnancy, 593-606
- Pituitary gland
 defects causing anovulation, 91-93
 function in adolescence, 1145-1146
 gonadotropins of. *See* Gonadotropins
 and reproductive function, 24-27
 tumors of, hyperprolactinemia in, 131
- Placenta
 abruption of
 and fibrinogen degradation products in serum, 348
 ultrasonic diagnosis of, 323
 aspiration of cells in, 330
 in breech presentations, 520
 enzyme studies in hypertension with pregnancy, 631-632
 localization with ultrasound, 322-323
 in preeclampsia-eclampsia, 884
 previa, ultrasonic signs of, 323
 transplacental passage
 of infectious agents, 459-460
 of proteins, 300
- Placental lactogen, 363-371
 assay in hypertension with pregnancy, 633
- Plasminogen, in follicular fluid, 47-48
- Podophyllin, in condyloma acuminatum, 987, 1070-1071
- Polyarteritis, in pregnancy, 389-390, 419, 900
- Polycystic kidney disease, in pregnancy, 420
- Polycystic ovarian disease, 99-112
 androgen levels in, 100-102
 estrogen levels in, 102-104
 etiologic factors in, 108-112
 gonadotropin levels in, 104-106
 hirsutism in, 99, 122
- Polycystic (*continued*)
 pathophysiology of anovulation in, 106-108
 symptoms of, 99-100
- Postmaturity
 and estriol analysis in urine, 356
 placental lactogen levels in, 368-369
- Potassium, renal handling of, 850-851
- Potter's syndrome, 832-833
- Povidone-iodine, in vulvar lesions, 983-984
- Prazosin, in hypertension with pregnancy, 638
- Precocious puberty, 75-81
- Preeclampsia-eclampsia, 881-894
 blood changes in, 885
 blood vessels in, 884
 brain in, 885
 and control of eclampsia, 399-402
 diet in, 891
 edema in, 886
 etiology of, 882
 and fibrinogen degradation products in serum, 348-350
 fluids and electrolytes in, 891
 α -2-glycoprotein levels in, 347
 heart in, 885
 hypertension in, 886, 889. *See also*
 Hypertension in pregnancy
 incidence of, 883-884
 liver in, 885
 magnesium sulfate in, 892
 pathogenesis of, 884-888
 placenta in, 884
 prognosis of, 893-894
 proteinuria in, 888
 renal lesions in, 877-878, 884, 889-890
 sedatives in, 891-892
 sodium retention in, 887-888
 treatment of, 890-893
 water retention in, 887
 weight gain in, 887
- Pregnancy
 in adolescence, 1135-1232. *See also*
 Adolescence
 alcohol ingestion in, affecting newborn, 307
 amino acid levels in
 in amniotic fluid, 303
 relation to infant growth, 305
 in serum, 301
 autoimmune disorders in, 385-393
 bacterial infections in, 455-473
 bacteriuria in, 422-424, 870-871, 879, 921-926
 blood pressure in, 413, 431
 blood volume in, 413-414, 431
 calculi in, urinary, 420, 912-914, 927-928
 cardiac disease in, 429-440

Pregnancy (continued)

- cardiovascular alterations in, 430-431
- cardiovascular surgery in, 433-434
- collagen diseases in, 899-901
- cystography in, 939
- cytomegalovirus infection in, 479-480
- diabetes in, 443-451, 899. *See also* Diabetes
- energy requirements in, 298-299
 - in adolescence, 1205
- estriol analysis in, 353-361
- fetal heart rate monitoring in. *See* Heart rate monitoring
- α -fetoprotein levels in, 342-346
- fibrinogen and degradation products in, 347-350
- glomerular filtration rate in, 412-413, 856, 938
- glomerulonephritis in, 418-419, 879-880, 896-898
- glycoprotein levels in, 346-347
- hemolytic anemia in, autoimmune, 390
- herpes infection in, 477-479, 1015-1017
 - affecting infant, 1057-1058
- hyperparathyroidism in, 914
- hypertension in, 397-408, 619-646, 881-882.
 - See also* Hypertension in pregnancy
- kidney changes in, 411-414
- kidney disorders in, 414-425, 875-880, 894-904
 - diagnostic tests in, 937-944
- lupus nephritis in, 387, 419
- metabolism in, 443-444
- molar, ultrasonic diagnosis of, 323-326
- multiple. *See* Multiple gestation
- myasthenia gravis in, 392-393
- nephrotic syndrome in, 419-420, 879, 898-899
- nutrition in, 297-309
 - in adolescence, 1202-1208
- ovarian vein syndrome in, 910-912
- polyarteritis in, 389-390, 419
- preeclampsia-eclampsia in, 877-878, 881-894
- prolactin levels in, 128
- protein levels in
 - in amniotic fluid, 301-302
 - relation to infant growth, 305
 - in serum, 299-300, 341-350
 - in urine, 398, 413, 879-880, 888, 938
- pyelography in, intravenous, 939
- radioisotope renogram in, 941-943
- renal angiography in, 940
- renal plasma flow in, 939
- in renal transplant recipients, 421, 931-934
- rheumatoid arthritis in, 385-386, 900

Pregnancy (continued)

- and risk assessment in perinatal medicine, 287-294
- rubella in, 484-485
- sclerosis in, progressive systemic, 389, 419
- thrombocytopenic purpura in, autoimmune, 391-392
- and trauma to urinary tract, 917-918
- ultrasound techniques in, 311-326, 330
 - in hypertension, 630
 - in urologic disorders, 943
- ureteropelvic junction obstruction in, 908-910
- ureterovesical reflux in, 863-872, 939
- urinary concentration and dilution in, 939
- urinary tract alterations in, 907-908
- urinary tract infections in, 422-424
 - diagnostic tests in, 937-944
- urine sediment in, 937
- urologic surgery in, 907-919
- varicella in, 480-482
- Venezuelan equine encephalitis in, 483-484
- viral infections in, 477-486
- weight gain in, 413
 - in adolescence, 1205
- Prenatal examination, new approach to, 255-256
- Premature ejaculation, 223-228
- Premature rupture of membranes
 - infection in, 462-466
 - management of, 539
- Prematurity
 - and breech presentation, 512, 516, 525
 - and corticosteroids affecting lung maturation, 466, 542, 557-558
 - etiology of, 533-535
 - estrogen activity, 534
 - fetal corticosteroids, 534
 - oxytocin release, 534
 - progesterone deprivation, 534
 - prostaglandins, 535
 - and management of labor, 535-539
 - bed rest in, 535
 - ethanol in, 535-537
 - magnesium sulfate in, 539
 - progesterone in, 537
 - prostaglandin inhibitors in, 539
 - sympathomimetic drugs in, 537-538
 - and survival of very low birth weight infants, 542
- Prenatal diagnosis of fetal disorders
 - amniocentesis in, 330, 336-339
 - in Down's syndrome, 331, 333-334
 - estriol analysis in, 353-361
 - α -fetoprotein assay in, 330, 342-346

- Prenatal diagnosis (*continued*)
 in genetic disorders, 329-339
 in hemophilia A, 335
 in muscular dystrophy, 330, 335
 in neural tube defects, 336
 in Tay-Sachs disease, 334
 ultrasonic techniques in, 311-322, 330
- Progesterone
 in corpus luteum, 48
 in management of premature labor, 537
 maternal levels of, and premature labor, 534
 synthesis from cholesterol, 58
- Prolactin
 action of, 54-60
 control of release, 126
 factors affecting secretion of, 127
 in follicular fluid, 41
 hyperprolactinemia, 127, 129-135
 bromocriptine in, 135, 160
 diagnostic studies in, 133-134
 in hypothalamic disease, 130-131
 in hypothyroidism, 132
 in pituitary tumors, 131
 treatment of, 134-135
 metabolism of, 125-135
 abnormal, 129-135
 and ovarian cycle, 27
 receptors in granulosa cells, 42
 serum levels of, 128-129
- Prolapse of pelvic organs, urinary
 incontinence in, 759-773
- Promethazine, in labor, 497
- Pronephros, 820, 831
- Propranolol
 effects in pregnancy, 433
 in hypertension with pregnancy, 637
- Prostaglandins
 affecting myometrium, 140
 inhibitors of, in management of premature
 labor, 539
 and luteolysis, 48, 51
 and premature labor, 535
 receptors in granulosa cells, 42
 synthesis and release of, 140
- Prosthetic heart valves, and pregnancy risks,
 438-439
- Protein
 in amniotic fluid, 301-302
 dietary deficiency in pregnancy, 303-305
 fetal synthesis of, 300-301
 intake in adolescent pregnancy, 1205-1206
 serum levels in pregnancy, 299-300,
 341-350
 relation to infant growth, 305
 transplacental transmission of, 300
- Proteinuria, in pregnancy, 398, 413, 879-880,
 938
 in preeclampsia-eclampsia, 888
- Pruritus, vulvar, treatment of, 987, 1102-1104
- Psoriasis of vulva, 991-993, 1033, 1035
- Psychogenic factors
 in dyspareunia, 210-212
 in impotence, 229, 232-233
 in premature ejaculation, 225-226
 in urinary incontinence, 701, 709, 745-747,
 807-815
- Psychological issues, in adolescent
 pregnancies, 1156-1158, 1162
- Psychophysical methods, for pain relief in
 labor, 495-496
- Pubertal development, 67-85, 1137-1140. *See*
also Adolescence
 delayed puberty, 81-84
 and hypergonadotropic hypogonadism,
 81-83
 and hypogonadotropic hypogonadism,
 83-84
 treatment of, 84
 and menometrorrhagia, 84-85
 normal, in females, 67-75
 in polycystic ovarian disease, 109-112
 and precocious puberty, 75-81
 diagnosis of, 79-80
 heterosexual precocity, 79
 pseudoprecocious puberty, 78
 treatment of, 80-81
 true, 76-78
- Pubic hair growth, in puberty, 1140-1142,
 1143-1144
- Puerperium
 acute renal failure in, 422
 uterine infections in, 467-473
- Purpura, autoimmune thrombocytopenic, in
 pregnancy, 391-392
- Pyelography, intravenous, in pregnancy, 939
- Pyelonephritis, in pregnancy, 424, 870-872,
 879, 922
- Pyoderma, of vulva, 1000-1002
- Radiation dosage, in mammographic
 screening, 4, 7
- Radiation therapy
 in melanoma, 1126
 in prolactin-secreting pituitary tumors, 135
- Radioisotope renogram, in pregnancy, 941-
 943
- Radiology
 in fetal maturity evaluation, 549
 in prenatal diagnosis of fetal disorders,
 329-330

- Reflux, ureterovesical, in pregnancy, 863-872, 939
- Renin production, affected by
 antihypertensive agents, 645
- Renogram, radioisotope, in pregnancy, 941-943
- Reproductive cycle, normal, 17-28
 and central nervous system function, 20-24
 feedback mechanisms in, 19-20
 and pituitary function, 24-27
- Reserpine, in hypertension with pregnancy, 637
- Resuscitation of newborn, 597-602
- Rh isoimmunization
 determination in adolescent abortion patients, 1181
 α -fetoprotein levels in, 345
 and management of newborn, 606
 and ultrasonic diagnosis of fetal ascites, 319-320
- Rheumatic heart disease, in pregnancy, 432
- Rheumatoid arthritis, in pregnancy, 385-386, 900
- Risk assessment, in perinatal medicine, 287-294
- Roll-over test, in screening for pregnancy-induced hypertension, 403
- Rubella, in pregnancy, 484-485
- Rupture of membranes, premature
 infections in, 462-466
 management of, 539
- Sacrospinous ligament fixation, transvaginal, 768-772
- Scalp blood analysis, fetal, 582-585
 oxygen values in, 589-590
- Scar, atrophic, of vulva, 1032
- Schistosomiasis
 intradermal test in, 971
 serologic tests for, 969
 smears in, 971
- Sclerosis, progressive systemic, in pregnancy, 389, 419, 900
- Screening tests
 for diabetes in pregnancy, 447
 for hypertension in pregnancy, 403
 mammographic, evaluation of, 1-13
 for rubella susceptibility, 485
- Sedatives, in preeclampsia-eclampsia, 891-892
- Serotonin, and prolactin release, 126
- Sex education programs, failures of, 1154-1155
- Sex roles, in formerly married persons, 261-262
- Sex steroids. *See also* Androgens; Estrogens
 action of, 61-66
 in follicular fluid, 41
 and gonadotropin secretion, 22-23, 57-58
 and pituitary function, 24
 secretion in childhood, 69
- Sexism, and gynecologic practice, 173-180
- Sexual activity
 patterns in adolescence, 1152-1154, 1161-1162, 1199-1200
 and transmission of vulvar diseases, 959, 1041-1050
 in young women, and counseling programs, 235-248
- Sexual maturation, in puberty, 1130-1142
- Sexual problems
 and adequate sexual response, 187-188
 in cancer patients, 196
 case histories of, 188-189
 with clitoral hood adhesions, 195
 and communication between partners, 199
 contraceptives affecting, 197-198
 counseling in, 191-202
 and diagnosis and treatment of pathology, 194-197
 drug-induced, 195
 in dyspareunia, 186, 189, 194, 205-217
 environmental factors in, 185, 188
 history-taking in, 183-190
 hormonal factors in, 195
 with hymeneal strand, 196
 impotence, 228-233
 and interference with arousal, 186-187, 188-189
 and lack of knowledge, 186, 189, 192
 male, gynecologic implications of, 223-233
 and mental distractions, 186-187, 189, 193-194
 pain in, 186, 189, 194, 205-217
 in pelvic floor relaxation, 196
 and physical examination as teaching method in, 197
- postmenopausal, 269-277
 case reports of, 270, 271, 274-275
 cultural factors in, 273-274
 estrogen therapy in, 275-277
 and loss of libido, 270
 and pelvic atrophic changes, 274-275
 and premenopausal orgasmic dysfunction, 271-273
- premature ejaculation, 223-228
 prevention of, 201-202
 and role of gynecologist, 191-202
 stimulation evaluation in, 184-185, 188
 in stress incontinence, 195

- Sexual problems (*continued*)
 and vaginal size, 196
 in vaginismus, 186, 189, 195, 218-220
 in vaginitis, 194-195, 209
- Sheehan's syndrome, anovulation in, 92
- Simmonds' disease, anovulation in, 92
- Skin, microanatomy of, 1117-1120
- Smears, in vulvar diseases, 970-971
- Social factors, in adolescent pregnancy, 1152-1153
- Social Readjustment Rating Scale, 265-266
- Sodium
 excretion in pregnancy, 857
 intake in adolescent pregnancy, 1206
 renal handling of, 848-850
 restriction in pregnancy, 432
 retention in preeclampsia-eclampsia, 887-888
- Sphingomyelin/lecithin ratio, in amniotic fluid, 553-555
 in hypertension with pregnancy, 631
 in infants of diabetics, 450
- Spinal cord, and neural control of urethrovaginal function, 658-662
- Spironolactone, in hypertension with pregnancy, 640
- Staphylococcal infections, of vulva, 1000-1002
- Stein-Leventhal syndrome. *See* Polycystic ovarian disease
- Stents, ureteral, 915
- Sterilization, voluntary, in teenagers, 1212
- Steroids. *See* Corticosteroids; Sex steroids
- Stevens-Johnson syndrome, 1017-1019
- Streptococcal infections
 in pregnancy, 466-467
 of vulva, 1001-1002
- Stress urinary incontinence, 649-815
- Surgery
 cardiovascular, in pregnancy, 433-434
 cesarean. *See* Cesarean section
 in condyloma acuminatum, 1072
 in melanoma, 1125-1126
 in pituitary tumors, 134-135
 in urinary incontinence, 764-805
 failure of, 791-794
 urologic, in pregnancy, 907-919
 in vulvar diseases, 973-982
- Sympathomimetic drugs, in management of premature labor, 537-538
- Symphiotomy, in breech presentation, 516
- Syphilis, 1047-1050
 clinical aspects of, 1048-1049
 serologic tests in, 968, 1049-1050
- Syphilis (*continued*)
 smears in, 970, 971
 treatment of, 1050
- Tampons, lost, management of, 244-245
- Tay-Sachs disease, carriers of, 334
- Temperature control, for newborn, 602-603
- Testosterone
 production in normal females, 116-117
 receptors in granulosa cells, 34-35
 serum levels of, 74
 in childhood, 1144
- Testosterone-estradiol-binding globulin, 117-118
- Testosterone propionate ointment, in lichen sclerosis of vulva, 984-986, 1102
- Tetralogy of Fallot, and pregnancy, 436-437
- Theca interna, development of, 36
- Thelarche, premature, 77-78
- Thiazide diuretics, in hypertension with pregnancy, 640
- Thrombocytopenic purpura, autoimmune, in pregnancy, 391-392
- Thyrotropin-releasing hormone, and prolactin secretion, 126
- Tinea, in vulvar area, 996-998
- Tocodynamometry, 569
- Toluidine blue test, in vulvar disorders, 967, 1104
- Toxemia of pregnancy
 α -fetoprotein levels in, 345
 and fibrinogen degradation products in serum, 348-350
 β -1-glycoprotein levels in, 346
 placental lactogen levels in, 366
- Transplantation of kidney, pregnancy after, 421, 931-934
- Trauma
 in breech presentations, 523
 or urinary tract, in pregnancy, 917-918
- Treponema pallidum*, identification of, 970, 971, 1049-1050
- Triamcinolone, injections in pruritus of vulva, 1102
- Triamterene, in hypertension with pregnancy, 640
- Trichloroacetic acid, in condyloma acuminatum, 1070
- Trichomonal infections
 culture specimens in, 970
 management of, 244
 smears in, 970
- Tuberculosis, renal, in pregnancy, 420, 895-896

- Tubular system, renal, 828
in pregnancy, 413
- Tumors
action of steroid hormones on, 65
carcinoma of vulva. *See* Vulva
and evaluation of mammographic screening,
1-13
hormonal responsiveness of cells in, 60,
65-66
hypothalamic, anovulation in, 94
melanoma, 1117-1132
vulvar, 1127-1131
ovarian
anovulation in, 90-91
and sex precocity, 78
Paget's disease of vulva, 1107-1114
pelvic, ultrasonic diagnosis in pregnancy,
326
pituitary
anovulation in, 92-93
hyperprolactinemia in, 131
and sexual problems in cancer patients, 196
urinary tract, in pregnancy, 918-919
- Turner's syndrome, 89-90
- Twin pregnancy. *See* Multiple gestation
- Ulcerations, vulvar, 959-960
- Ultrasound in obstetrics, 311-326, 330
with amniocentesis, 322-323, 337-338
bladder fullness affecting, 323, 338
fetal studies with, 311-322, 330
in anencephaly, 315
in death in utero, 321-322
and evaluation of maturity, 312, 549
in fluffy fetus, 320
in gastrointestinal lesions, 319
and heart rate monitoring, 566-567
in hydrocephalus, 315
identification of anatomic structures,
313
location and development, 311-312
in maternal disease with fetal
involvement, 319-320
in meningomyelocele, 317
in multiple gestation, 314-315
recognition of anomalies, 315-319
in renal lesions, 319
small-for-gestational-age recognition,
312-313
in hypertension, 630
in molar pregnancies, 323-326
in pelvic masses, 326
for placental localization, 322-323
in urologic disorders, 943
- Urea therapy, in hypertension with
pregnancy, 640
- Ureter
anatomy of, 824-825
duplications of, 836-839
ectopic orifice of, 754-755
hormones affecting, 859-860, 866-867
indwelling stents in, 915
innervation of, 830
in pregnancy, 857-861, 907-908
trauma in pregnancy, 918
- Ureteropelvic junction, obstruction in
pregnancy, 908-910
- Ureterovesical reflux, in pregnancy, 863-872,
939
and anatomy of vesicoureteral junction,
863-865
clinical implications of, 870-872
cystourethrography in, 870
physiology of, 865-869
- Urethra, 666-667
anatomy of, 824-825
diverticula of, 752-753
electromyography of sphincter, 672-673,
683-684, 720-721
embryology of, 823
pressure studies in incontinence, 713-715
sphincter activity in urinary incontinence,
673-678, 685-690
absence of, 673-674
with detrusor dyssynergia, 677-678
dyssynergia of, 675
with hypotonic bladder, 674-675
with uninhibited detrusor contraction,
676-677
- Urethritis, 755-756
- Urethrocystography, metallic bead-chain,
725-735, 778, 789-790
- Urethrocystoscopy, carbon dioxide, 711, 713,
737-757
- Urethropexy, retropubic, 775-784
- Uric acid levels, in pregnancy, 856-857
- Urinos monitor, in urinary incontinence,
721-723
- Urinary incontinence, 649-815
and absence of sphincter activity, 673-674
from bladder disease, 734
bladder pressure in, 690-691, 714
bladder sensation in, 690
in cystocele, 761
cystometry in. *See* Cystometry
in descent of bladder neck, 761-762
with detrusor dyssynergia and normal
sphincter, 677-678

Urinary incontinence (*continued*)

- with detrusor-sphincter dyssynergia, 675-676
- drugs affecting, 747-752
- and ectopic ureteral orifice, 754-755
- and electromyography of urethral sphincter, 672-673, 683-684, 720-721
- in estrogen deprivation, 747, 749, 762
- examination in, 710, 776-778, 788-789
- and history of patient, 705-710, 776, 788
- with hypotonic bladder and normal sphincter, 674-675
- in massive genital prolapse, 762-763
- metallic bead-chain urethrocystography in, 725-735, 778, 789-790
- and neural control of muscle function, 653-667
- and neurogenic bladder, 701, 743, 744
- and patterns of detrusor and sphincter activity, 673-678, 685-690, 699-701
- and postural detrusor hyperreflexia, 689-690
- psychogenic, 701, 709, 745-747, 807-815
 - case reports of, 811-814
- recurrent, 733, 787-796
 - treatment of, 794-796
- and sexual problems, 195
- surgery in, 764-805
 - and correction of perineal defect, 772-773
 - failure of, 791-794
 - partial bladder denervation in, 797-805
 - and restoration of vaginal depth and axis, 767
 - retropubic urethropexy in, 775-784
 - sacrospinous ligament fixation in, transvaginal, 768-772
- selection of procedure in, 731-733
- with uninhibited detrusor contraction, 676-677, 688-690
- urethral pressure in, 713-715
- in urethritis, 755-756
- urethrocystoscopy in, carbon dioxide, 711, 713, 737-757
- urgency component in, 701
- Urilos monitor in, 721-723
- urinalysis in, 711
- uroflowmetry in, 711-713, 739, 744
- videocystourethrography in, 715-720

Urinary tract

- anatomy of, 819-830
- calculi in pregnancy, 420, 912-914, 927-928
- changes in pregnancy, 411-413, 907-908
- embryology of, 819-824, 831-832
- infections in pregnancy, 422-424, 870-872, 921-928

Urinary tract, infections (*continued*)

- acute infections, 927
- diagnostic tests in, 937-944
- innervation of, 828-830
- lymphatics of, 830
- obstructions in pregnancy, 908-912
- physiology of, 845-852
- trauma in pregnancy, 917-918
- tumors in pregnancy, 918-919

Urine

- concentration of, 847
 - in pregnancy, 939
- dilution of, 847-848
 - in pregnancy, 939
- drainage of
 - with indwelling ureteral stents, 915
 - with percutaneous nephrostomy, 915
- sediment in pregnancy, 937

Uroflowmetry, in urinary incontinence,

711-713, 739, 744

Urography, in pregnancy, 894-895, 907-908

Uterus

- bacterial infections in pregnancy, 455-473
- cervical barrier against bacterial flora, 457
- molecular biology of contractions in, 140-141
- monitoring of activity in labor, 569-571
- display with fetal heart rate, 566
- prostaglandins affecting, 140

Vaccines

- in condyloma acuminatum, 988, 1063-1064, 1072-1076
- in cytomegalovirus infection, 480
- in melanoma, 1126-1127
- in rubella, 485
- in varicella, 482
- in Venezuelan equine encephalitis, 484

Vagina

- discharge from, management of, 243-245
- self-dilation methods in dyspareunia, 215-217
- size of, and sexual problems, 196

Vaginismus, 186, 189, 195, 218-220

definition of, 218-219

etiology of, 219-220

management of, 220

Vaginitis

- from rectal intercourse, 244
- and sexual problems, 194-195, 209
- Varicella, in pregnancy, 480-482

Ventilation procedures, for newborn, 597-600

Veratrum alkaloids, in hypertension with pregnancy, 644

Verruca genitalis, 1033, 1035-1036

Videocystourethrography, 715-720

Viral infections

- in pregnancy, 477-486
 - cytomegalovirus, 479-480
 - hepatitis, 482-483
 - herpes, 477-482, 1015-1017
 - rubella, 484-485
 - varicella, 480-482
 - Venezuelan equine encephalitis, 483-484
- of vulva, 1053-1059
 - condyloma acuminatum, 1061-1076
 - herpes, 1053-1059

Vitamin A therapy, in lichen sclerosis of vulva, 1104

Vitamin B₆

- in dysmenorrhea, 141-142, 144
- in hyperprolactinemia, 135

Vitamin requirements, in adolescent pregnancy, 1207-1208

Vitiligo, of vulva, 1029

Vulvar diseases, 951-1133

- actinobolites in, 987-988
- atrophic disorders, 1032
- Bartholin's cyst or abscess, 966, 973, 975-977
- betadine in, 983-984
- biopsy in, 966
- blood studies in, 968-969
- bullous diseases, 1007-1021
 - differential diagnosis of, 1020, 1021
- candidiasis, 998-999, 1033, 1035
- carcinoma
 - and condyloma acuminatum, 1065-1066
 - dystrophies related to, 1098-1100
 - 5-fluorouracil in, 988
 - and herpesvirus infections, 1058
 - in situ, 1033, 1036
- cellulitis, 1001
- chancroid, 1046-1047
- classification of, 955-961
- condyloma acuminatum, 1061-1076
- condyloma latum, 1033, 1036
- contact dermatitis, 1002-1004
- cryosurgery in, 979-980
- culture specimens in, 969-970
- curettage in, 965-966
- cutaneous, 957-958
 - bullous, 1007-1021
 - infections, 957-958, 996-1002
 - inflammations, 991-996, 1002-1004
 - melanoma, 1127-1131
- cytologic studies in, 967
- dermatitis herpetiformis, 1019, 1020
- diagnosis of, 963-971
- dye-light therapy in, 984

Vulvar diseases (continued)

- dysplasia, 1087-1090
- dystrophies, 1025-1029, 1081, 1104
 - hyperplastic, 1028-1029, 1083-1090, 1101
 - mixed, 1028, 1095-1098
 - pathogenesis of, 1098
 - relation to cancer, 1098-1100
 - symptoms of, 1100-1101
 - treatment of, 1101-1104
- ecthyma, 1001
- electrosurgery in, 977-978
- with erosions or ulcerations, 959-960
- erysipelas, 1001
- erythema multiforme, 1017-1019, 1020
- erythrasma, 999-1000
- examination in, 964-965
- excision of lesions in, 966, 973-975
- fluorescence studies with Wood's light, 968
- folliculitis, 1001
- gentian violet in, 973, 983
- granuloma inguinale, 1041-1043
- herpesvirus infections, 1053-1059
 - gestationis, 1015-1017
- histologic examination in, 965-966
- history-taking in, 957-964
- hormone therapy in, 984-987
- hypertrophic disorders, 1033-1037
- immunofluorescence studies in bullous disease, 966-967
- immunotherapy in, 988
- impetigo, 1001
- intertrigo, 1033
- laser therapy in, 980-982
- lichen planus, 993-994, 1029
- lichen sclerosis, 1025-1028, 1090-1095
 - in childhood, 1104
 - treatment of, 1101-1102
- lichen simplex chronicus, 995-996, 1033, 1035, 1083
- lymphogranuloma venereum, 1043-1046
- marsupialization in Bartholin cysts, 966, 975-977
- medical treatment in, 982-988
- melanoma, 1127-1131
- neurodermatitis, 995-996
- Paget's disease, 1107-1114
- patch testing in, 968, 1003
- pemphigoid
 - benign mucous membrane, 1014-1015, 1020
 - bullous, 1013-1014, 1020
- pemphigus, 1007-1013, 1020
 - familial benign chronic, 1011-1013
- pruritus in, treatment of, 987, 1102-1104
- psoriasis, 991-993, 1033, 1035

Vulvar diseases (*continued*)

- pyodermas, 1000-1002
- seborrheic dermatitis, 994
- sexually transmitted diseases, 959, 1041-1050
 - smears in, 970-971
 - surgery in, 973-982
 - syphilis, 1047-1050
 - tinea, 996-998
 - toluidine blue test in, 967, 1104
 - treatment of, 973-989
 - undetermined disorders, 959
 - verruca genitalis, 1033, 1035-1036
 - viral infections, 1053-1059
 - condyloma acuminatum, 1061-1076
 - herpesvirus, 1053-1059
 - vitaligo, 1029
 - vulvovaginal, 958
 - white lesions in, 960, 1023-1038, 1081
 - invariably white, 1025-1031
 - potentially white, 1025, 1032-1037
- Vulvovaginitis, 958

Warts, genital, 1033, 1035-1036. *See also*
Condyloma

Water retention, in preeclampsia-eclampsia, 887

Weight

- at birth. *See* Birth weight
- gain in pregnancy, 413
 - in adolescence, 1205
 - affecting infant, 305
 - in preeclampsia-eclampsia, 887
- gain in puberty, 1139-1140
- White lesions of vulva, 960, 1023-1038, 1081
- Wickham's striae, in lichen planus, 993
- Widows, counseling of, 259-266
- Women
 - counseling of. *See* Counseling
 - health care for, attitudes in, 173-180
 - normal female development, 67-75
- Wood's light fluorescence studies, in vulvar disease, 968
- Word catheter, in Bartholin abscesses, 973, 977

Zatuchni-Andros scoring system, in breech presentations, 526

Zinc

- deficiency in pregnancy, 308
- intake in adolescent pregnancy, 1207

